



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

September 01, 2018

To,
The Listing Department,
BSE Ltd.

Sub: Outcome of Board Meeting held on September 01, 2018.

We wish to inform you that the Board Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses:

1. The Board approved the preferential issue of upto 13,74,000 equity shares of Rs. 10/- each at a premium of Rs.75/- each to promoters and non-promoters subject to the approval of the shareholders and BSE Ltd. **(List annexed)**
2. Approved the notice of the extra ordinary general meeting ("**EGM**") and fixed the date time and venue for the same.

The EGM is scheduled to be held on Saturday, September 29, 2018 at 11:30 A.M.

In accordance with SEBI (LODR) Regulations, 2015 and the Companies Act, 2013, the Company is providing the facility of voting through electronic means, as an alternate, to all its members to enable them to cast their votes electronically.

The following are details of the same:

S. No	Particulars	Details
1	E-voting start date	September 26, 2018 - 9:00 A.M
2	E-voting end date	September 28, 2018 - 5:00 P.M
3	Cut-off date for e-voting	September 22, 2018

The Company has appointed Mr. Tapasvilal Deora, Company Secretary in Practice as "Scrutinizer" for conducting the e-voting process for the EGM in a fair and transparent manner.

Please also find enclosed the press release to be made in this regard.



The meeting commenced at 11.30 A.M. and concluded at 8:00 P.M.

This for your information and dissemination to the public.

For VANTA BIOSCIENCE LIMITED
Scrip Code: 540729 Scrip ID: VANTABIO

Zohel
ZOHEB SAYANI
COMPANY SECRETARY




S. No. Name of Proposed Subscribers

Promoters

- 1 Dopesh Raja Mulakala
- 2 Vyas Madhavrao Shingatgeri

Non Promoters

- 3 Shalendra Goswami
- 4 Tetris Consultants Llp
- 5 Mitesh C Sheth
- 6 Gothamchand A
- 7 S S Seema
- 8 Arwa Umesh
- 9 Amit Gunchandra Mehta
- 10 Prem Ratan Bhaiya Huf
- 11 Rohil Jain
- 12 Balaji Equities
- 13 Aparna Thakker
- 14 F L Dadabhoy Jointly With P F Dadabhoy
- 15 Usha Pande Jointly With Harish Pande
- 16 K Vishwanath
- 17 Hemangini Thaker
- 18 Kishorekumar Nanaji Sonekar
- 19 Tushar Shantilal Soni
- 20 Leena Sachin Shetty
- 21 Ajaya Sharma
- 22 Kailash Sancheti F Huf
- 23 Manju Bansal
- 24 Manoj Kumar D
- 25 Manju Gupta
- 26 Meghji Murji Shah
- 27 Ajit Dedhia
- 28 Jasmin Dedhia
- 29 Amish Dedhia
- 30 K. Venkat Rao
- 31 K.Deepthi
- 32 K. Siddarth
- 33 T.V Sambashiva Rao
- 34 S. Venkat Rao



Press Release

Vanta Bioscience Ltd. Approves Issue of Shares on Preferential basis to Fund Its Foray Into Clinical Research Business

Mumbai. 01 September 2018. In a Board Meeting held at Hyderabad today, Vanta Bioscience Limited approved the issue of 13,74,000 equity shares of Rs. 10 each at a premium of Rs. 75 each on preferential basis to a select group of investors. The preferential issue represents 24% of the total paid up capital of the Company. The aggregate amount raised through preferential route will be used for financing its wholly owned subsidiary Vanta Clinical Research Limited for setting up of its foray into Clinical Research business.

Said Mr. S. Venkat Rao, CEO, Vanta Bioscience Limited, "We are confident that this investment in Clinical Research business will help build comprehensive solutions for our clients and generate a top line of over Rs. 250 crores from clinical research business in five years."

Considered as a major milestone, the preferential issue is subject to approval by shareholders at their Extra Ordinary General Meeting scheduled to be held on 29 September 2018.

After its foray into Clinical Research, Vanta Bioscience Limited will be among the select few companies in India offering comprehensive solutions in this field.

About Vanta Bioscience Limited

Vanta Bioscience Limited, a BSE SME Exchange Listed Company, is a pre-clinical contract research company, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, it also provides risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. Besides, The Company also provides expert services for determination of health-based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharma sector. Among the major services of Vanta Bioscience is conducting of variety of in-vitro (cell, tissue & organisms) and in-vivo (animal) toxicology studies for its diverse clients as per regulatory requirements from across the world. The Company has research laboratories in Chennai, India and is managed by industry veterans and experts. Complying with OECD GLP, ISO, AAALAC & USFDA GLP (21 CFR Part 58) guidelines, Vanta has been established as a center of excellence for OECD GLP toxicology services. More information can be availed on: www.vantabio.com

For more information, kindly contact:

Priya Panvekar
Raka Reputation Management Services Pvt. Ltd.
Mobile: 7045654080

Vanta Bioscience Limited
Mobile: +91 98662 72052

